http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#Head http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#assertion http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#provenance http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#pubinfo http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#assertion http://purl.obolibrary.org/obo/DOID_9538 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9538 http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08910 http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association http://www.w3.org/2000/01/rdf-schema#label pomalyst is a thalidomide analogue indicated in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 6 days of completion of the last therapy 1 1 pomalyst in combination with dexamethasone is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 6 days of completion of the last therapy http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08910 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#provenance http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#pubinfo http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#sig http://purl.org/nanopub/x/hasSignature eexbn+e6FdL1dTmywQbI2yGrIwH4DENS8j594/Rnj4wpiyXTe/5/DiZgSgbqUvG9ae0AUG+wyAXgCC/sdzuxGrDTFJa8ZlRVgjOKB5dGTE9P/TJYiMEyWZ3dlAxxlCX0hurwxRu/l+yfzWxikNx/Mp6Eq7/nxfHUgR6b9UHf/JM= http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 http://purl.org/dc/terms/created 2021-06-12T14:48:20.601+02:00 http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs